Mesa Laboratories, Inc. Form 10-Q Summary
Business context and reporting period
This filing covers the three months ended June 30, 2014, Mesa Laboratories’ first quarter of fiscal 2015. The company develops and sells quality-control products through its Biological Indicators, Instruments, and Continuous Monitoring divisions. Its products serve regulated healthcare, pharmaceutical, industrial, environmental, and related markets.
The request metadata identifies “2013 Q1,” but the filing text clearly reports the quarter ended June 30, 2014, with June 30, 2013 as the comparable period.
Key financial metrics
| Metric | Three months ended June 30, 2014 | Three months ended June 30, 2013 |
|---|---|---|
| Revenue | $16.400 million | $11.218 million |
| Gross profit | $9.705 million | $6.797 million |
| Gross margin | 59% | 61% |
| Operating income | $3.055 million | $3.043 million |
| Net income | $1.881 million | $1.860 million |
| Net margin | 11% | 17% |
| Diluted EPS | $0.51 | $0.52 |
| Operating cash flow | $0.426 million | $2.805 million |
Revenue increased 46%, while gross profit increased 43%. Operating expenses rose 77% to $6.650 million, including higher selling costs, personnel costs, amortization, acquisition-related expenses, and research and development. Other expense increased to $162,000, primarily because of higher interest expense.
Cash and cash equivalents were $3.200 million at June 30, 2014, compared with $5.575 million at March 31, 2014. Working capital was $15.686 million, versus $16.351 million at March 31, 2014. Accounts receivable rose to $10.761 million and inventories rose to $9.950 million.
Total debt was $28.000 million, consisting of $13.000 million under the line of credit and a $15.000 million term loan, of which $3.000 million was classified as current. As of July 31, 2014, the company reported $25.750 million of outstanding indebtedness and $8.500 million of unused credit capacity. The company was in compliance with its debt covenants at June 30, 2014.
Material changes versus the prior comparable period
- Revenue increased by $5.182 million, or 46%, reflecting acquisitions and organic growth.
- Biological Indicators revenue increased 32% to $6.417 million, aided by the Amilabo acquisition, organic growth, price increases, and the absence of prior-year replacement-product costs.
- Instruments revenue increased 21% to $7.685 million, driven by the BGI acquisition, the SureTorque product line, and 6% organic growth in existing product lines.
- Continuous Monitoring contributed $2.298 million of revenue and $994,000 of gross profit; it had no comparable prior-year revenue because of the timing of acquisitions.
- Gross margin declined to 59% from 61%. Instruments margin declined to 64% from 67% because of BGI integration and product mix, while Continuous Monitoring margin was 43% and remained affected by integration activities.
- Operating income was essentially unchanged despite higher revenue because operating expenses increased substantially.
- Operating cash flow declined $2.379 million, primarily due to higher accounts receivable and working-capital needs.
- Investing cash use increased to $14.210 million, including $13.817 million for acquisitions and $393,000 for capital expenditures.
- Financing activities provided $11.409 million, including $18.000 million of new borrowings, partly offset by $6.500 million of debt repayments and $526,000 of dividends.
Guidance, outlook, risks, contingencies, and unusual items
Management expects biological-indicator markets to remain strong because the products are disposable and supported by regulatory requirements. Instrument and Continuous Monitoring demand remains strong, but these businesses are more sensitive to economic conditions and discretionary customer capital spending.
Management expects Continuous Monitoring integration activities to be substantially completed by the beginning of the second half of fiscal 2015, with expected improvement in that segment’s gross margin. The company is also pursuing research and development projects that may produce new products in the coming year.
Management stated that cash from operations, available credit, and potential financing sources should be sufficient for short- and long-term needs. Expected uses include dividends, debt payments, capital expenditures, acquisitions, and implementation of a new ERP system over the next 9–12 months, which may require significant cash.
- The April 2014 BGI acquisition had a preliminary purchase price of $10.268 million and generated $3.295 million of goodwill and $5.711 million of intangible assets. The purchase price allocation remained subject to adjustment.
- The April 2014 Amilabo acquisition and prior Amega and TempSys acquisitions increased selling, administrative, amortization, and integration costs.
- Potential contingent consideration ranges from $0 to $10.000 million under the Amega agreement and from $0 to $6.710 million under the Bios agreement. Recorded liabilities were $500,000 and $1.120 million, respectively.
- The company has estimated state sales-tax exposure of $1.408 million recorded in accrued expenses; ultimate liability may change.
- Debt is secured by company assets and subject to a maximum funded-debt-to-EBITDA ratio of 2.5 to 1.0 and a minimum fixed-charge coverage ratio of 1.35 to 1.0.
- Management reported no material changes to previously disclosed risk factors, minimal foreign-currency and commodity-market exposure, and effective disclosure controls and internal controls over financial reporting. The evaluation excluded acquired entities, which represented 7.8% of quarterly revenue.
- The board declared a $0.15-per-share quarterly dividend payable September 15, 2014.
Important facts for investors to verify
- Reconcile the significant revenue growth with the contribution and integration costs of BGI, Amilabo, Amega, and TempSys.
- Monitor whether Continuous Monitoring margins improve after the expected completion of integration activities.
- Assess cash conversion, particularly the decline in operating cash flow and increases in receivables and inventory.
- Review debt maturities, required term-loan amortization, interest-rate exposure, unused credit capacity, and covenant compliance.
- Evaluate the potential cash impact of contingent consideration, state sales-tax exposure, acquisition obligations, and the planned ERP implementation.
- Confirm the final valuation and purchase price allocation for the BGI acquisition, including goodwill and intangible assets.